

## PlexEBV

**Intended Use:** PlexEBV is a lab-developed blood test to measure the level of cellular immunity to the Epstein-Barr virus (EBV). Decreased anti-EBV immunity increases the risk of EBV infection.\*

**Purpose:** Knowledge about immunity to EBV and therefore the risk of EBV infection can be combined with available clinical data to plan additional treatment for your patient. EBV can also cause lymphoma in some patients who are heavily immunosuppressed or whose immune system is compromised severely. EBV immunity can be low in such patients.

**Procedure:** PlexEBV measures functional cell-mediated immunity to the Epstein-Barr virus.

Whole blood, 3 ml from children, 5 ml from adults in sodium heparin green top tubes, is shipped at ambient temperature overnight to Plexision's reference laboratory

- EBV-specific T-cells and their subsets, which express the inflammatory marker, CD154 are measured after stimulation with EBV viral protein.
- Simultaneously, recipient T-cell stimulation with mitogen measures general T-cell responsiveness.

### Performance: Results

- **Are reported within 30 hours** after blood samples reach the laboratory
- are reported as frequencies of EBV-specific T-cells and their subsets along with thresholds for the level of EBV immunity. These thresholds have been established from studies of transplant recipients. These thresholds determine whether immunity to EBV is decreased or not.
- Low immunity to EBV can be associated with persistently high EBV viral load

**References:** US Patent 9606109

\*PlexEBV is not FDA-approved